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Abstract Recent studies showthatViagra and methamphet-
amine use are associated with unprotected anal intercourse
among men who have sex with men (MSM). In Long Beach,
California, we have reported on an association between
Viagra use and the use of amphetamines during sex. The
current research investigated the use of both Viagra and
amphetamine in men in Long Beach, California. Data on
1,839 men recruited into HIV prevention and testing pro-
grams were collected using the Risk Behavior Assessment. A
generalized logit model was constructed comparing ever
having used both amphetamine and Viagra together and
separately, as compared to never having used either (refer-
ent). Men who used both methamphetamine and Viagra
showed a significantly higher prevalence of hepatitis B,
syphilis, and HIV compared to those who used only one or
neither drug. Of the 1,794 complete cases, 11.1% (199/1794)
had used both amphetamine and Viagra. Of 20 potential risk
and protective factors for use of amphetamine and Viagra, 12
were significant predictors: ever used gamma-hydroxybuty-
rate (GHB), ever used cocaine, ever used ecstasy, being in-
fected with HIV, race = White compared to other, ever
having hepatitis B, ever using crack, ever given money to have
sex, living in a hotel, ever been in drug treatment, and ever
using heroin. The protective factor was being heterosexual.
Viagra use was associated with insertive, and methamphet-
amine was associated with receptive, anal intercourse. GHB
use appears to play a more important role than previously
thought.
Keywords Methamphetamine  Viagra  Drug abuse 
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Introduction
Polydrug use that combines methamphetamine with other
drugs has been documented in several studies (Halkitis &
Green, 2007; Patterson, Semple, Zians, & Strathdee, 2005;
Rawstorne, Digiusto, Worth, & Zablotska, 2007). These
studies have tended to focus on street drugs, such as ecstasy,
cocaine, heroinand Ketamine. Recently, however, researchers
have begun to report on the concurrent use of methamphet-
amine and Viagra (sildenafil citrate) prior to and during
sexual encounters (e.g., Mansergh et al., 2006; Semple, Zians,
Strathdee, & Patterson, 2008). These studies indicate that
while methamphetamine and Viagra are both independently
associated with high-risk sexual behavior, the behavioral risks
and associatedoutcomesare significantly greater foruserswho
combine both drugs. Spindler et al. (2007) reported that the
prevalence of unprotected insertive anal sex with a male
partner of unknown or different HIV status within a sample of
men who have sex with men (MSM) was 19.1% for users of
Viagra alone and 22.6% for users of methamphetamine alone.
Prevalence rates jumped to 46.9% when methamphetamine
was combined with Viagra. The increasing popularity of the
combined use of methamphetamine and Viagra suggests that
use of this sex-drug cocktail is worthy of a broader consider-
ation, as it may identify a subgroup of individuals who are at
even greater risk of HIV and sexually transmitted disease
(STD) acquisition than those who use methamphetamine or
Viagra alone or neither drug.
According to the World Health Organization, illicit use of
methamphetamine among all drug use is second only to
cannabis (Rawson, Anglin, & Ling, 2002). MSM who use
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methamphetamine consistently report engaging in risky
sexual behavior, including unprotected insertive and recep-
tive anal sex (Crosby & Mettey, 2004; Halkitis, Mukherjee,
& Palamar, 2007; Mansergh et al., 2001; Patterson & Semple,
2003; Schwarcz et al., 2007) and several reports indicate that
these users are at increased risk for acquisition of HIV and
other STDs (Patterson & Semple, 2003; Schwarcz et al.,
2007; Semple, Zians, Grant, & Patterson, 2006). Within Los
Angeles county, MSM who use crystal methamphetamine
are five times more likely to test positive for HIV than MSM
who do not use the drug (Rosenblatt, 2007). Although MSM
may be at increased risk for HIV infection compared to het-
erosexuals, risky sexual behavior is not exclusive to MSM.
Research indicates that adolescent and adult heterosexual
users of methamphetamine also report having multiple sex
partners and engaging in unprotected sex while under the
influence (Molitor, Truax, Ruiz, & Sun, 1998).
Although originally developed as a medical aid to combat
erectile dysfunction, recreational use of Viagra is not un-
common (Halkitis, Mukherjee et al., 2007; Mansergh et al.,
2001). Like methamphetamine, recreational use of Viagra is
strongly associated with risky sexual behavior and HIV
(Crosby & DiClemente, 2004; Fisher et al., 2006; Swearin-
gen & Klausner, 2005). Independent examinations of the
behavioral risks associated with methamphetamine and the
risks associated with recreational use of Viagra have found a
dissimilar pattern of behavioral associations. For example,
while the recreational use of Viagra has been found to be
associated with unprotected insertive anal intercourse (UIA),
reports on methamphetamine use by MSM have found use of
the drug to be associated with unprotected receptive anal
intercourse (URA) (Schwarcz et al., 2007).
These findings highlight an important distinction with
respect to methamphetamine and Viagra use. Previous re-
ports have identified methamphetamine use by MSM for the
purpose of mood and energy to counteract the negative affect
associated with HIV? serostatus (Semple, Patterson, &
Grant, 2002) or within the context of raves and circuit parties
(Halkitis, Parsons, & Stirratt, 2001; Lee, Galanter, Dermatis,
& McDowell, 2003; Ross, Mattison, & Franklin, 2003).
Within these contexts, the use of methamphetamine may be
incidental to sex (Ross et al., 2003). However, the linking of
methamphetamine use with Viagra clearly places metham-
phetamine use strictly within the context of sex. This con-
nection was previously noted in a study on Viagra use (Fisher
et al., 2006) which found that the combination of metham-
phetamine and Viagra was reportedly used both before and
during sex. This was further supported by reports suggesting
that the recreational use of Viagra was associated with risky
sexual behavior and not used solely for the purpose of
enhancing sexual performance (Colfax et al., 2001).
The present study examined the combined use of meth-
amphetamine and Viagra within a sample of men living in the
Long Beach, California area with the following specific aims:
(1) to examine the prevalence of methamphetamine and
Viagra use men in Long Beach-South Bay, California; (2) to
examine the incremental demographic and behavioral cor-
relates of methamphetamine and Viagra use; and (3) to
characterize the infectious disease risk of the combined use of
methamphetamine and Viagra. Using ‘‘no use of either drug’’
as the reference category, we constructed a multinomial logit
model and compared behavioral risks associated with using




Between May 2001 and July 2007, data were collected on
1,839 men between the age of 15 and 88 years (M = 40.66
years, SD = 11.27) residing in the Long Beach, California
area. Participants were recruited through three HIV preven-
tion and/or HIV/STD testing programs operated by the
Center for Behavioral Research and Services at California
State University, Long Beach. One program provided HIV/
AIDS prevention counseling for gay and bisexual men, one
provided HIV/AIDS prevention counseling for illicit drug
users and heavy alcohol users, and one provided HIV, STD,
and hepatitis testing for a variety of behavioral risk groups. It
was also possible for any client to use more than one program
if they qualified. Sample demographics included 44.7%
White, 24.5% Black, 21.3% Hispanic, and 9.7% other. Of the
total sample, 47.5% identified as men who have sex with men
(MSM)/men who have sex with men and women (MSMW)
and 52.5% identified as heterosexual. HIV positive preva-
lence was 7.0% of those tested in the total sample.
Measures
Risk Behavior Assessment (RBA)
The RBA is a 20–30 min, structured interview developed by
the Community Research Branch of the National Institute on
Drug Abuse (NIDA) in collaboration with the NIDA Cooper-
ative Agreement for Community-Based Outreach/Intervention
Research grantees. The RBA is administered by trained inter-
viewers and asks questions related to HIV risk behaviors (e.g.,
drug use, needle sharing, and sexual behaviors), drug history,
health history and status, work status, and income. Specific
drug use variables include lifetime use or nonuse, age of first
use, frequency of use during the most recent 30 day period
(i.e., number of times used and number of days used).
These assessments were made for alcohol, marijuana, cocaine
(crack, powdered, and injection), heroin, speedball (heroin and
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cocaine mixed together), nonprescription methadone, other
opiates, and amphetamine. Sexual risk behaviors included
number of sexual partners during the most recent 30 day period,
frequency and type of sexual activity, use of condom or barrier
protection, and whether sex had been traded for drugs and/or
money. The test–retest reliability of most of the questions and
48-h validity of the drug use variables have been found to be
acceptable to very good (Dowling-Guyer et al., 1994; Fisher,
Kuhrt-Hunstiger, Orr, & Davis, 1999; Fisher, Reynolds, Jaffe,
& Johnson, 2007; Needle et al., 1995).
Designer Drug Trailer (DDT)
The DDT is an addendum to the RBA and assesses use of
designer drugs. The format for the DDT was similar to the
RBA and included questions about lifetime use and nonuse,
age of first use, and frequency of use during the most recent
30-day period (i.e., number of times used and number of days
used). Drugs assessed included methylene-dioxymetham-
phetamine (MDMA), Ketamine, gamma hydroxybutyrate/
gamma-butyrolactone (GHB/GHL), 2C-T-7, 2C-B, 5-MeO-
DIPT (Foxy or Foxy methoxy), 2-MTA, Rohypnol, and
Viagra.
Procedure
All participants were interviewed in individual sessions. At
the beginning of each session, participants provided in-
formed consent and were allowed to ask questions following
protocols approved by the Institutional Review Board at
California State University, Long Beach. Interview sessions
lasted approximately 1.5 h, during which time each partici-
pant was administered the RBA and DDT and completed
several self-administered questionnaires. The conclusion of
each session varied by program; however, all participants
were given incentives for participation as well as referrals to
other services as needed. All data collected for this project
were protected by certificates of confidentiality.
Statistical Analysis
The data were analyzed using a multinomial logit model,
sometimes referred to as a generalized logit model (Allison,
1999; Hosmer & Lemeshow, 2000; McFadden, 1973). The
data were analyzed in SAS 9.1.3 service pack 4. Because of
missing values on one or more variables, only 1794 (97.55%)
of the data were used. There were four classifications of the
data: those who did not use either drug (n = 762) was the
referent group. The referent group was compared to: (1) those
who used methamphetamine only (n = 715), (2) those who
used Viagra only (n = 118), and (3) those who used both
methamphetamine and Viagra (n = 199).
Results
The proportion of those using methamphetamine immediately
before or during sex in the methamphetamine-only group was
lower (24%) than in the group using both methamphetamine
and Viagra, where it was 33% v2(1, N = 542) = 3.83, p =
.0502. This demonstrated that the use of methamphetamine
was more closely associated with sexual activity for those who
used both methamphetamine and Viagra.
Table 1 shows the percentage of participants in each drug
group who tested positive to six different laboratory tests.
The four tests for sexually transmitted infections (hepatitis B
core antigen, HIV, and two tests for syphilis (TP-PA and
RPR) all showed significant differences in proportions and
the drug group with the highest percentage for three of these
four tests was the group using both methamphetamine and
Viagra.
Table 2 shows the results of the generalized logit model
comparing those who only used methamphetamine to the
referent group, which was those who did not use either drug.
The strongest risk factors were use of GHB/GHL and use of
cocaine. Other drug risk factors were use of crack, ecstasy,
and heroin. The methamphetamine-only group was also more
likely to report being positive for HIV. Table 3 shows the
results of the generalized logit model comparing those who
only used Viagra to those who did not use either drug. Again,
the strongest risk factors were use of GHB/GHL and cocaine.
There was more emphasis on sex risk and less on drug risk in
this group, so the risk factors of ever given money to have sex
and the number of people had sex with distinguished the
Viagra-only group from the referent group, but crack,
ecstasy, and heroin were not significant risk factors for the
Viagra only group. Being HIV positive was not significant.
Table 4 shows the generalized logit model comparing
those who used both methamphetamine and Viagra to those
who did not use either drug. The major drug risk factors were
use of GHB/GHL, cocaine, and ecstasy, in addition to crack








Both v2 n p
Hepatitis A 47.8 45.1 44.0 41.5 1.27 649 ns
Hepatitis B 13.0abc 22.8b 26.5c 31.7a 18.5 631 .0003
Hepatitis C 64.0 61.0 66.7 44.1 3.51 157 ns
HIV 3.8ab 8.2b 3.2 9.5a 11.06 1021 .0114
TP-PAa 4.0abc 8.8b 15.6c 15.3a 16.1 580 .0011
RPRb 1.6ac 4.4 6.7c 8.3a 9.5 582 .0233
Note: In all cases df = 3. Proportions in the same row that share the same
subscript differ at p \ .05 in pairwise v2 comparisons
a Serodia TP-PA qualitative gelatin particle agglutination assay
b ASI rapid plasma reagin test
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and heroin. Both HIV and hepatitis B entered the model as
risk factors and ever given money to have sex was also a risk
factor. This was the only model that included hepatitis B.
In order to further explicate the model, the frequency of
both insertive and receptive anal sex reported by both gay and
heterosexual men was examined. Table 5 shows the means
(separately for gay and straight) of the number of times
participants reported having both receptive and insertive anal
intercourse in the 30 days before interview. One-way AN-
OVAs of Drug use group on both receptive anal intercourse
and insertive anal intercourse were performed for the gay
men only because the frequencies of the behaviors were too
low for the heterosexual men for meaningful statistical
analysis. It is clear that, for the gay men, the group that used
both methamphetamine and Viagra had the greatest mean
number of both receptive and insertive anal intercourse. The
significant comparison was between the group that did not
use either drug and the group that used both methamphet-
amine and Viagra for insertive anal sex; the significant
comparison for receptive anal sex was between the Viagra
only group and the group that used both methamphetamine
and Viagra. Correlation analysis assisted with further inter-
pretation. For the gay men who used both drugs, there was a
significant positive correlation between number of times
used amphetamine immediately before or during sex and
number of times had receptive anal intercourse r(98) = .21,
p = .04. There was a non-significant inverse correlation
between number of times used amphetamine immediately
before or during sex and number of times had insertive anal
intercourse r(98) = -.01.
Discussion
Data from a sample of men were used to construct a multi-
nomial model (consisting of three separate comparisons)
comparing those who used methamphetamine, Viagra, and
both methamphetamine and Viagra, to a referent group of
those who used neither methamphetamine nor Viagra. The
Table 2 Generalized logit comparing those using methamphetamine




Ever used GHB/GHL 1.94 6.8 2.71, 17.93
Ever use cocaine by itself 1.66 5.3 3.90, 7.08
Ever been told infected with HIV 0.97 2.6 1.40, 4.99
Ever use crack 0.96 2.6 1.83, 3.69
Are you living in a hotel 0.93 2.5 1.52, 4.21
Ever used ecstasy 0.79 2.2 1.50, 3.26
Ever been in drug treatment or detox 0.73 2.1 1.49, 2.89
White 0.62 1.9 1.40, 2.47
Ever use heroin 0.52 1.7 1.19, 2.38
Note: All odds ratios are significant if the 95% confidence interval does
not include 1





Ever used GHB/GHL 1.81 6.1 1.78, 21.09
Ever use cocaine by itself 0.75 2.1 1.31, 3.44
White 0.66 1.9 1.29, 2.93
Ever given money to have sex 0.62 1.9 1.09, 3.17
How many people had sex with 0.13 1.14 1.01, 1.27
Do you consider yourself heterosexual -0.95 0.4 0.22, 0.69
Note: All odds ratios are significant if the 95% confidence interval does
not include 1
Table 4 Generalized logit comparing those using both methamphet-




Ever used GHB/GHL 2.38 10.8 4.30, 28.80
Ever use cocaine by itself 1.99 7.3 4.38, 12.24
Ever used ecstasy 1.84 6.3 3.89, 10.29
Ever been told infected with HIV 1.36 3.9 1.85, 8.21
White 1.13 3.1 2.07, 4.65
Ever been told have hepatitis B 1.12 3.1 1.69, 5.61
Ever use crack 1.07 2.9 1.73, 4.92
Ever given money to have sex 0.89 2.4 1.57, 3.78
Are you living in a hotel 0.82 2.3 1.17, 4.41
Ever been in drug treatment or detox 0.70 2.0 1.24, 3.26
Ever use heroin 0.56 1.7 1.05, 2.88
Do you consider yourself heterosexual -1.18 0.3 0.18, 0.52
Note: All odds ratios are significant if the 95% confidence interval does
not include 1
Table 5 Drug use groups by sexual preference compared on anal
intercourse type and mean frequency in 30 days
Intercourse type Neither drug Meth only Viagra only Both
M (SD) M (SD) M (SD) M (SD)
Gay
Insertive anal 1.7 (4.26)a 2.7 (5.71) 2.3 (4.55) 4.0 (17.69)a
Receptive anal 1.4 (3.58) 1.6 (3.96) 0.8 (1.29)b 2.1 (5.41)b
Straight
Insertive anal 0.5 (2.07) 0.4 (1.82) 0.4 (1.88) 0.9 (3.72)
Receptive anal 0.01 (0.13) 0.01 (0.24) 0.0 (0.00) 0.0 (0.00)
Note: Frequencies of behavior for straight men were too low for
meaningful statistical analysis. One-way ANOVA (gay only) for Drug
Group on insertive anal sex F(3, 964) = 2.98, p = .03. One-way AN-
OVA (gay only) for Drug Group on receptive anal sex F(3, 964) = 2.54,
p = .055. Means in the same row that share a subscript differ at p \ .05
in the Tukey honestly significant difference comparison
276 Arch Sex Behav (2011) 40:273–279
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major risk factor in all three comparison models was use
of GHB, which was both strong and consistent. GHB was
originally developed as an anesthetic (Freese, Miotto, &
Reback, 2002). An epidemic of GHB abuse started in the late
1980s, which our data suggest is still continuing (Nicholson
& Balster, 2001). Its use in conjunction with Viagra has been
reported in New York (Halkitis & Palamar, 2006; Halkitis,
Palamar, & Mukherjee, 2007), San Francisco (Colfax et al.,
2001), Los Angeles, and Chicago (Carey et al., in press). We
strongly agree that the recreational use of GHB has been
understudied (Halkitis & Palamar, 2006) as our findings point
to a very strong association between the use of GHB and the
use of both methamphetamine and Viagra.
Cocaine was also a strong risk factor that was consistent
across the drug groups, although not as strong as GHB. This is
not surprising in the model comparing methamphetamine
use, given that they are both stimulants and that this model
also included ecstasy, which is also a stimulant. Cocaine use
has been found to be associated with unprotected anal inter-
course in young MSM and the only drug associated in mul-
tivariate analysis with failure to use condoms (McNall &
Remafedi, 1999). A nationwide study found that cocaine use
was associated with both unprotected receptive and insertive
anal sex (Koblin et al., 2003). In a California study, cocaine
use was associated with unprotected anal intercourse in both
bivariate and multivariate analysis (Molitor, Facer, & Ruiz,
1999). In our findings, cocaine use was the second strongest
predictor in all three models. Even though our findings were
in agreement with other published reports, this consistency in
our top two predictors across our three models is noteworthy.
Furthermore, there was a strong association between the
models and the differences in prevalence of the infections.
Very few other reports have attempted to distinguish type
of anal intercourse and associations with different drugs. Two
reports that did make this attempt showed an association of
methamphetamine with receptive anal intercourse that would
agree with our findings (Mansergh et al., 2006; Rusch, Lampi-
nen, Schilder, & Hogg, 2004). For gay men, receptive anal
intercourse was lowest in the Viagra only group. The gay men
who used both methamphetamine and Viagra reported the
highest mean frequency of both receptive and insertive anal
intercourse. In addition to having more receptive anal inter-
course, theyalsoappeared tobehavingmore insertiveanal sex.
Their higher amount of receptive anal sex was related to their
use of methamphetamine as shown by the significant corre-
lation between the use of amphetamine immediately before or
during sex and the number of times had receptive anal inter-
course. One report showed Viagra taken in combination with
methamphetamine was associated with insertive anal inter-
course (Spindler et al., 2007). We would argue that this effect
was due to the Viagra and not the methamphetamine (Fisher
et al., 2006; Mansergh et al., 2006).
Overall, non-White men were less likely to report using
both methamphetamine and Viagra than White men. This
finding was strongest in the comparison of those who used
both drugs to those who used neither drug. The association
between methamphetamine and anal intercourse, and Viagra
and anal intercourse has been reported to be more common
among White men (Carey et al., in press). Other researchers
have also reported that Black men were less likely to use
methamphetamine and Viagra (Halkitis & Green, 2007).
Number of sex partners only entered the model comparing
those who used Viagra only to those who used neither drug.
Ever having given money to have sex was also a factor in both
the Viagra only comparison as well as the Viagra and meth-
amphetamine comparison. The only protective factor was
being heterosexual, that is, those who were heterosexual were
less likely to be in the Viagra only group or the Viagra and
methamphetamine group as compared to the group who used
neither drug. This was not true for the methamphetamine only
group comparison.
In conclusion, our data showed that those gay men who
take both Viagra and methamphetamine engaged in higher
levels of risky sex, and as a consequence, had a significantly
higher prevalence of hepatitis B, untreated syphilis, and HIV.
Although not significant, even the heterosexual men who
took both drugs had higher frequencies of insertive anal sex.
There have been calls for warning labels for Viagra as well as
for scheduling Viagra as a controlled substance (Klausner &
Swearingen, 2004; Swearingen & Klausner, 2005). Our data
would suggest that Viagra by itself may not be the culprit,
but rather the combination of methamphetamine and Viagra.
This would suggest that methamphetamine abuse and/or
dependence should be a contraindication in Viagra prescrib-
ing. GHB also probably plays a more important role than
previously thought and needs to be investigated to a much
greater extent. Future research should be careful to distin-
guish type of anal intercourse and which drug is associated
with insertive as compared to receptive anal intercourse. Our
findings support the notion that Viagra is associated with
insertive, and methamphetamine is associated with recep-
tive, anal intercourse. Men who take both Viagra and meth-
amphetamine are at much higher risk for hepatitis B, HIV and
untreated syphilis because they engage in much higher rates
of anal intercourse than any of the comparison groups.
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